Drugmaker Zydus Cadila said that it has received approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep among COVID-19 patients. The trials will start in December and will be conducted on 250 patients across 20 to 25 centres in India. The company said that it is also conducting a similar phase 2 trial in Mexico and working with the US Food and Drug Administration (USFDA) to open an Investigational New Drug (IND) application for PegiHep in order to initiate appropriate clinical trials in America.
